SLC5A2 and heart failure: To be more accurate, SGLT2 inhibitors as the drugs that stimulate urinary glucose excretion according to their pivotal outcome trials (EMPA-REG OUTCOME trial, CANVAS Program, DECLARE-TIMI 58) have considerably reduced mortality in type 2 diabetes, most likely not driven by a reduction in atherothrombotic events but through prevention of heart failure [10,11,12].